On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please list the outcome(s) not met. It met all outcomes primary and secondary according to all those listed at clinicaltrials.gov.
Same crap, different day. It has always been Leo's (and my contention) that certain milestones needed completion before a partnership or license agreement. That time is now upon us. February has always been the weakest month of the year for biopharma stocks. We are now exiting that period and entering a spring upswing with very strong clinical performances. Those are facts, Jack.
Kevetrin results were not what many here falsely characterized. The recent phase 2 met all endpoints and outcomes. It even confirmed the need for a pill form to extend systemic exposure for a drug with a very short half-life. Further, many wrongly asserted the need for starting from zero, when, in fact, there will be a quick bridge study followed by Phase 2c, optimization and efficacy. With newly acquired increased knowledge of MOA, Phase 2c might even be a drug combination trial. In any case, soon there will be a bottom line data release that will clear up many misperceptions and false assertions.
Please read again my response to your post. One can’t simultaneously argue data is insufficient for one projection and then argue that same evidence points to the opposite. This is especially true when that same conclusion is based on omitting all previous supporting (preclinical) evidence to the contrary.
Complete bullshit based on nothing. The same data you point to as in sufficient to assume a dose dependent curve can’t be used to formulate an opposite thesis simply because one wants to show a likelihood. In fact, using the data, insufficient or not, points to exactly the opposite conclusion of likelihood.
“Those who have the kahunas to endure this will benefit huge!”
Hey! Watch the spelling!
Cajones: testicular fortitude. Spanish slang.
Kahunas: a group of highly educated spiritual or social leaders. Formal Hawaiian.
From a certain viewpoint, maybe both are true here with IPIX?
Pretty sure it will open lower in the morning, but slow fingers will miss the bottom. Month change next Wednesday will usher in a trend change. First data release as soon as early March.
Why are you being disingenuous by pretending the CEO's loan should be treated like other corporate loans and somehow adds urgency to funding when it doesn't? The CEO isn't going to put his tens of millions of shares at risk by taking any action against the company.
Why are you being disingenuous by pretending the CEO's loan should be treated like other corporate loans and somehow adds urgency to funding when it doesn't? The CEO isn't going to put his tens of millions of shares at risk by taking any action against the company.
That info is in every K and Q.
To who are the liabilities owed? They are owed to the CEO. Of course those liabilities are completely sustainable.
You always lend such great insight. I had no idea Pfizer and Novartis have earnings. Wow, how long has that been going on?
Sure you can get in or out. You just have to hit .68 and then .69 and then .6985 when MMs start zip coding the ask. What about getting out? Accept that you will be getting .66 after .665. Of course, the minute your sell fills, those shares will be offered at .68. Efficient market is actually in the MM’s job description.
You mean the stock-based compensation? You mean the issuance of shares that he has yet to sell? Do you mean the bonus in shares for hitting targets such as completion of 4 trials in the 12 month period with costs under target budget? You mean the non-cash bonus that has been reduced by about 30% in value since December 31? You mean that bonus? Not knowing the details of the award, I’d still say he did quite a bit for a bonus that’s still tied to future performance.
So, you think employees in biopharma make $14,000 a year? I don’t think even the partime janitor makes that. For most employees, I think you are off by maybe a quantum.
Or, let P pay for B-OM, -UP, -UC, ABSSSI, Acne, etc.
Do you mean this trial was removed from clinicaltrials.gov?
https://clinicaltrials.gov/ct2/show/NCT02949388?term=Prurisol&rank=2
The primary outcomes were met. Read the dam things again.
Not released yet. But the outcome uses a dozen or so metrics, not just tumor reduction.
Read the primary outcomes again. All were met. That is not a failure as you have stated.
You need to read the 10q and the trial again. IPIX has been working on oral K for a year. It was a parallel development. The 10q states only that they stopped recruiting and they will start a similar trial once oral K is ready.
I’m not the one twisting facts. I even posted the trial outcomes to back up what I said.
Finally, none of us know what Menon is up to or the full story of why his salary was cut. It could be anything from his becoming a consultant for a partner to he is preparing for retirement in the near future. The final 3 years of my university gig I enjoyed a phased retirement. My final year was 2 courses as a workload for all of 2017-2017, at half pay. You don’t know what the facts are.
It met the primary outcomes. That was the trial design, to further understanding of K MOA.
“In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to evaluate the pharmacokinetics of Kevetrin when administered to subjects with platinum-resistant/refractory ovarian cancer.”
And,
“Primary Outcome Measures :
Incidence of Treatment-Emergent Adverse Events [ Time Frame: 6 Weeks ]
Reporting of Adverse Events, and severity of adverse events
Evaluate changes in biomarkers between pre-treatment sample and post-treatment sample [ Time Frame: 3 Weeks ]
Changes in RNA and/or protein level of pre-specified biomarkers associated with the p53 signalling pathway and apoptosis will be compared between pre-treatment sample (tumor biopsy, ascites fluid, and peripheral blood) and post-treatment sample (tumor biopsy, ascites fluid, and peripheral blood)”
https://clinicaltrials.gov/ct2/show/NCT03042702?cond=Ovarian+cancer+Kevetrin&rank=1
They met primary outcomes and will now work on an oral formulation before continuing with a new Phase 2 following a bridge study.
Thanks for the investment platitudes. For example: “Never go against the trend.” What if there is no current trend, but a high likelihood of a new trend in the
term?
Anyone following your “advice”, especially warnings about nonexistent threats from preferred shares, will be missing out on huge gains in the coming months.
The only thing I agree with is no one should have more than 5% in a high risk stock unless it is the result of appreciation. Would tax free trading resulting in substantially increased shares count as appreciation?
There is a 100% chance he pulled that 50% number out of his [hat].
You’re wrong. Those are total short sales, not short interest at the end of the day. Trades are made in 2 parts, a sale and a buy, or a buy and a sale. Buys that are executed without covering shares are short trades. Most short trades are covered before the end of the day.
Complete nonsense. There is no reason for such a dilutive finance vehicle when all others remain untapped. As I said, makes no sense no matter how much I think about it.
There is a possibility of rain in Dubai during August. It’s not going to happen, but it is possible. It’s the same with IPIX and those shares you are afraid of. The CEO from late October through December only tapped some 47k shares of Aspire’s millions available. With the likelihood of a fat deal in the next 6 months, and with a few multiples of $5 million left in the Aspire tranche, why would he use the most dilutive option for funding? It makes no sense, none at all.
Nickel flippers are done for now. Nice correction for midday and should be some strength into the close. The test for follow through should be tomorrow.
Complete fabrication. There is absolutely no evidence for such an assumption.
IPIX has been disconnected from the broad market for an entire year. There is no reason for it to connect now as partnerships loom. Profits from there will find their way here in the coming days.
Leo has not used convertibles, doesn’t need to and won’t need to. He still has a lot left with Aspire funding as well as completely untapped private placement. Your claim is ridiculous.
My opinion is based on my total experience trading all stocks including penny stocks since 1986. The penny stocks you refer to don’t have 6 drugs in clinical trials AND spend less than $17 million a year for 10 years. Your referred penny stocks burn through that every quarter to get into clinical trials and then burn rate goes higher for phase1. IPIX ain’t even close to being one of those.
Management has had plenty of time the last 3 years to issue those shares to themselves and others and then reverse split. Instead, they have issued only enough shares to finance trials, business costs and salaries. Warrants have also been kept to a minimum. This is not one of your typical scam pink sheets. This is a real Biopharma, with 6 drugs in clinical trials, and still only spending 12-15 million a year.
Those shares are to protect against hostile takeovers of the technology. Please read the structure, conditions and ways in which they can be issued. I’m sure Loanranger can provide a link. I’m too busy looking to pick up more shares for my ROTH.
Yesterday’s Update, point by point
1) there are now nearly 20 CDAs with several more under review.
2) there is in place bulk production for the base drug, Brilacidin, by an international manufacturer. (Keep in mind the bulk Brilacidin is then formulated into the IV, oral, rinse, salve, foam, etc)
3) IPIX is now actively pursuing dermatology Brilacidin, “including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need...”
4) “the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018.” (Now that almost no systemic exposure to Brilacidin has been established, a topical drug will come under a different and far less time consuming system of clinical trials.)
When assigning a possible valuation, "no failures" is more important than you seem to think. There is plenty of evidence available from recent mergers and acquisitions.
There are 3 platforms. Two, Brilacidin and Kevetrin, are arguably each worth more than $5 in a buyout, at the present time. We've already seen evidence of each IBD indication exceeding a billion each. $10 billion would be a minimum in a buyout, even at the current stage. Just because a flawed market doesn't reflect that doesn't mean it's not the case.
There are other manners in which the SP can go to $20 more quickly. A deal for B is likely to be for all IBD and OM (if not the entire B platform). Recently there have been platform deals that closed with half a billion up front a more than a billion in milestones. Half a billion in the bank with a small multiplier of 2 would yield an SP of >$6. The price could easily spike to $20 on covering and buying, but would correct quickly and steeply. Seen this scenario.
Announcement of such a deal on a Monday morning before open would crush short interest by not allowing an escape from steep losses without paying the new premium.
Another would be a flat buyout. Leo and Menon aren't spring chickens anymore. They might take a deal that would include Menon retaining royalties, Leo getting a board seat and Dr. B retained by Big Pharma for 2 years of transition and a fat check. Such a manner would instantly make the SP the buyout offer, probably >$50.
Yeah, all of the above are fairly remote possibilities, but I've seen stranger and more radical in things BioPharma Land when there have been no failures.
Depends on the drug, its use and it’s therapeutic target. Efficacy can be measured in lots of ways. In a trial against resistant tumors in terminal patients, yeah a primary outcome must be some measure of life extension whether tumor arrest or tumor reduction. But, those outcomes were t really the most important for both Kevetrin trials. The most critical outcomes are those involving MOA as well as other PK/PD metrics.
The interesting thing about Kevetrin is that there are efficacy signals in all measures. And, whether or not that one critical one that patients are most hopeful emerges from the data set, may or may not come out of the OM trial. But, most importantly will be the fuller understanding of Kevetrin’s actions, the most critical part of this small study. Yes, the numbers will be too small to mean anything regarding changes in mortality, but these 10 added to those previous will increase reliability of all signals whatever they are.
You really don’t know what efficacy for Kevetrin means? You think it’s limited to survival? It’s a p53 modulating drug. All the literature on cancer and p53 explain a modulating drug’s place in therapy, yet your standard is purely limited to the question of survival time and whether or not Kevetrin by itself extends that? You really don’t get what this is all about at all.